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Abstract
Costimulatory molecules play a central role in the development of cellular immunity. Understanding how costimulatory
pathways can be directed to positively influence the immune response may be critical for the generation of an effective HIV
vaccine. Here, we evaluated the ability of intravenous administration of a blocking monoclonal antibody (mAb) directed
against the negative costimulatory molecule CTLA-4, and an agonist mAb directed against the positive costimulatory
molecule 4-1BB, either alone or in combination, to augment intramuscular SIV DNA immunizations. We then tested the
ability these of these responses to impact a high-dose SIVmac251 challenge. Following immunization, the groups infused
with the anti-4-1BB mAb exhibited enhanced IFN-c responses compared to the DNA vaccine only group. Interestingly,
although CTLA-4 blockade alone did not enhance IFN-c responses it did increase the proliferative capacity of the CD4
+ and
CD8
+ T cells. The combination of both mAbs enhanced the magnitude of the polyfunctional CD8
+ T cell response. Following
challenge, the group that received both mAbs exhibited a significant, ,2.0 log, decrease in plasma viral load compared to
the naı ¨ve group the included complete suppression of viral load in some animals. Furthermore, the use of the CTLA-4
blocking antibody resulted in significantly higher viral loads during chronic infection compared to animals that received the
4-1BB mAb, likely due to the higher CD4
+ T cell proliferative responses which were driven by this adjuvant following
immunization. These novel studies show that these adjuvants induce differential modulation of immune responses, which
have dramatically different consequences for control of SIV replication, suggesting important implications for HIV vaccine
development.
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Introduction
Costimulatory molecules play an important role in the
development of antiviral cellular immunity, which has been
extensively studied in the context of cancer immune therapy. Less
investigated is the role of how these costimulatory pathways
influence the immune response in the context of vaccination,
particularly in nonhuman primates. In this study we sought to
compare two different costimulatory adjuvants in the form of
antibodies targeted towards two surface expressed costimulatory
molecules (4-1BB and CTLA-4) that drive different immune
modulation phenotypes.
4-1BB is a member of the TNFR family of proteins and is a late
costimulatory molecule whose expression is induced by TCR
ligation and cross-linking of CD28 (as reviewed in [1]. It’s primary
role is in sustaining effector T cell responses by enhancing cell
survival [2] and proliferation as well as driving effector functions of
primed CD4
+ and CD8
+ T cells [3]. In regards to CD8
+ T cells
specifically, 4-1BB ligation of activated cells during the develop-
ment of the immune response drives robust increases in antigen-
specific IFN-c secretion as well as target cell killing [3]. These
functions seem to occur in both the setting of natural immunity [1–
3] as well as in the context of vaccination, as in a previous pilot
study in non-human primates, the administration of a 4-1BB
monoclonal antibody adjuvant was shown to enhance cytokine
production, cytolytic functions, and to drive CD8
+ T cells to an
effector (CCR7
2/CD45RA
+) phenotype following immunization
with an SIVgag DNA vaccine [4].
While the B7 (CD80, CD86) family of costimulatory molecules
positively stimulate T cell responses through CD28, such responses
may also be negatively regulated via costimulatory receptors. In
particular, cytotoxic T lymphocyte antigen 4 (CTLA-4)is a
costimulatory molecule found on T cells that negatively regulates
immune responses when bound by its ligand(s), CD80 and CD86
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responses, as its up-regulation is able to suppress immune function
and proliferation on antigen-experienced cells [6]. Blockade of
CTLA-4 signalling is possible via the administration of blocking
antibodies, and this phenomenon has been exploited for the
purposes of tumor immunotherapy. Blockade of CTLA-4 in this
context was shown to enhance anti-tumor immunity in humans
[7,8,9] primarily through T helper cell expansion/proliferation.
CLTA4 expression on T cells also has implications for infectious
disease as a correlation between CTLA-4 expression on CD4
+ T
cells and dysfunction in IL-2 production as well as disease
progression has been identified in HIV positive individuals [10].
The current study evaluated the ability of two monoclonal
antibodies (mAb), to enhance the immunogenicity of a SIV DNA
vaccine. We hypothesized that a blocking antibody directed
toward CTLA-4 would provide expansion primarily of a more T
helper phenotype while an antibody that served as a 4-1BB agonist
would provide more of a late costimulatory signal associated with
the induction of an effector T cell phenotype. These mAb were
infused into cynomolgous macaques during a DNA vaccination
protocol either individually or in combination. Interestingly, the
two mAb each enhanced the vaccine-induced immune response in
different ways. Infusion with the 4-1BB mAb resulted in higher
IFN-c responses while infusion with the CTLA-4 mAb resulted in
higher CD4
+ and CD8
+ T cell proliferative responses. When the
two mAb were delivered in combination the resulting IFN-c and
proliferative responses were of an intermediate level, while the
polyfunctional vaccine response induced in these animals were the
highest of any of the vaccinated groups. Following a high dose
SIVmac251 mucosal challenge, the animals that received both
mAb exhibited a significant 2-log decrease in peak viremia
compared to un-immunized controls. Interestingly, in the chronic
phase of infection, the CTLA-4 immunized group exhibited high
viral loads that were comparable to the un-immunized controls
and were significantly higher than the 4-1BB or the combination
adjuvant groups. This suggests that a vaccine response that
induces a strong effector response, i.e. cytokine production, may
be more protective than a response that induces highly
proliferative CD4
+ T cells, which may serve as targets for SIV
infection. Overall more than half the animals receiving 4-1BB
antibodies alone or in combination with CTLA-4 antibodies (7/
12) were able to completely suppress viral replication to
background levels by 25 weeks post challenge. This outcome
suggests that vaccine driven CD4
+ T cell proliferation alone may
not be beneficial for an HIV vaccine, whereas the induction of a
strong T cell effector response in conjunction with proliferative
capacity looks to be an important strategy to pursue for HIV
vaccination.
Results
Study Design
Groups of six cynomolgus macaques were immunized intra-
muscularly five times with consensus SIV gag, env, and pol
plasmid DNA (Table 1). On the day of each immunization, as
well as two days later, macaques were infused with 10 mg/kg of an
agonist anti-4-1BB mAb (4-1BB), a blocking anti-CTLA-4 mAb
(CTLA-4), both antibodies (Combo), or without (DNA) antibodies.
Five saline injected macaques served as naı ¨ve controls. Three
months following the final immunization, the animals were
intrarectally challenged with a high-dose, SIVmac251.
Activation of the 4-1BB pathway enhances Th1 responses
We first assessed the cellular response by a standard,
quantitative IFN-c ELISpot. After three immunizations the 4-
1BB group and the Combo group had the highest ELISpot counts
(708061108 and 666861347 SFU/10
6 PBMCs, respectively)
(Figure 1a). The CTLA-4 had lower IFN-c responses than the
DNA group (47936909 and 546861772 SFU/10
6 PBMCs,
respectively). The fourth and fifth immunization did not boost
this response.
To determine the relative contribution of CD4
+ and CD8
+ T
cells to the observed IFN-c response, PBMCs isolated following
the fourth immunization were depleted of CD8
+ T cells and IFN-c
production was measured by ELISpot (Figure 1b). In all
immunization groups, CD8
+ T cells comprised the majority
(,90%) of the IFN-c response.
We next wanted to assess the balance of Th1 and Th2 responses
in the vaccinated animals as CTLA-4 has been shown to inhibit
GATA-3, a transcription factor that drives Th2 responses in mice
[11]. Thus we were interested to see if CTLA-4 blockade would
promote a Th2 skewed response. To assess Th2 responses we
performed an IL-4 ELISpot on frozen PBMCs that were isolated
after the second immunization (Figure 1c). Animals that received
the CTLA-4 antibody, either alone or in combination with 4-1BB,
had similar IL-4 responses (5816165 and 5146125 SFU/10
6
PBMCs, respectively). These responses were four-fold higher than
the DNA (Mann-Whitney, p=0.009) and 4-1BB group (121651
and 128663 SFU/10
6 PBMCs, respectively). In addition, the
Combo group exhibited IL-4 responses that were significantly
higher than the 4-1BB group (Mann-Whitney, p=0.002).
CTLA-4 blockade enhances T cell proliferation
Studies of LTNPs have demonstrated that the proliferative
capacity of CD8
+ T cells is greater in LTNPs than in progressors
[12,13,14]. We performed CFSE proliferation assays to examine
the proliferative capacity of the vaccine-induced response. Despite
Table 1. Study design and immunization schedule.
Group (n=6) Vaccine Immunization (Study Days) Antibody
Antibody Infusion
(Study Days)
DNA SIVgag SIVenv SIVpol
(2 mg/construct)
0, 28, 56, 84, 630 None 4, 9, 30, 32, 58, 60, 86, 88
4-1BB BMS-663513 (10 mg/kg)
CTLA-4 Ipilimumab (10 mg/kg)
Combo BMS-66513+Ipilimumab (10 mg/kg)
Saline None None N/A
doi:10.1371/journal.pone.0024250.t001
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responses, CTLA-4 blockade in vivo greatly enhanced antigen-
specific proliferation of CD4
+ T cells and, to a lesser degree but
also impressively, CD8
+ T cells following peptide stimulation ex
vivo. Without this treatment the antigen-specific proliferative
capacity of CD4
+ T cells was low, with an average of
5.1864.14% and 8.6364.00% proliferation in the DNA and 4-
1BB groups, respectively (Figure 2a). However, animals receiving
CTLA-4 blockade demonstrated much higher CD4
+ T cell
proliferation, with an average response of 30.4667.53% prolifer-
ating cells, which was significantly higher than the DNA and 4-
1BB groups (Tukey test, p=0.008 and p=0.028, respectively).
The Combo group exhibited a slightly lower response of
22.7365.02%. In the absence of the CTLA-4 antibody treatment,
proliferation of CD8
+ T cells in the DNA and 4-1BB group
averaged 19.3866.75% and 17.3262.46% proliferating cells,
respectively (Figure 2b). CD8
+ T cells from anti-CTLA-4-treated
animals proliferated an average of 24.166.16% and 25.963.71%
in the CTLA-4 and Combo group, respectively. Together, these
data demonstrate the ability of in vivo of CTLA-4 blockade to
greatly enhance CD4
+ T cell proliferation in the non human
primate model.
Polyfunctional profile of CD4
+ T cells
Having observed modulation of vaccine-induced proliferative
responses, we were interested to see if there were differences in the
quality of the CD4+ T cell response. To assess the quality of the
vaccine-induced response, we employed polychromatic flow
cytometry to measure the production of IFN-c, IL-2, TNF-a,
and CD107a mobilization of antigen-specific CD4
+ T cells. The
magnitude of the total functional response was similar between the
DNA, 4-1BB, and CTLA-4 groups (0.36%, 0.25%, and 0.36%,
respectively) (Figure 3a). The Combo group exhibited a 1.5 fold
increase in frequency (0.60%) of antigen-specific CD4
+ T cells.
Figure 1. Modulation of Th1/Th2 responses following DNA vaccination with antibody adjuvants. An IFN-c ELISpot was used to measure
the Th1 response following each immunization (a). The relative contribution of CD4
+ and CD8
+ T cells to the IFN-c response was measured by ELISpot
following CD8
+ T cell depletion of PBMCs isolated after the fourth immunization (b). The Th2 response was assessed by IL-4 production. ELISpot assay
(c). Statistical differences between groups was determined by doing pair-wise Mann-Whitney tests with a Bonferroni adjustment with p values less
than 0.01 being significant (**=p,0.01). Pair-wise values: CTLA-4 vs. Saline or DNA (p=0.002, p=0.009, respectively); Combo vs. Saline, DNA, or 4-
1BB (p=0.002, p=0.002, p=0.009, respectively).
doi:10.1371/journal.pone.0024250.g001
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this functional response was predominantly CD28
+CD95
+ for all
vaccination groups, with groups ranging from 71% (DNA) to 93%
(CTLA-4) of the total response (Figure 3b). Using Boolean gating
we assessed the ability of individual cells to produce multiple
cytokines, i.e. polyfunctionality of the vaccine-induced CD4
+ T cell
response. Although the proportion of 4, 3, 2, and monofunctional
cells varied slightly in response to different antigens within a group,
there were trends observed between groups. The CTLA-4 and
Combo group had a larger proportion of their response driving
four functions compared to the DNA and 4-1BB groups
(Figure 3c). When the responses are then further divided into
the 15 possible functional combinations, we observed that all of the
vaccination groups induced the same populations, albeit at
different frequencies. There was a tendency for less IL-2
monofunctional cells in the 4-1BB group, which reflects the lower
proliferative capacity observed in the CFSE assay in this group
(Figure 3d).
Polyfunctional profile of CD8
+ T cells
We next examined the quality of the CD8
+ T cell response.
Similar to what was observed in the CD4
+ T cell compartment,
the DNA, 4-1BB, and CTLA-4 exhibited similar frequencies of
antigen-specific CD8
+ T cells (0.80, 0.86, and 0.63% respectively)
(Figure 4a). The Combo adjuvant group exhibited the highest
frequency of functional responses with 1.23% of CD8
+ T cells
capable of at least one function. In contrast to the CD4
+ T cell
compartment, the functional responses observed in the DNA and
4-1BB group were predominantly of the CD28
2CD95
+ memory
phenotype (71% and 77%, respectively) (Figure 4b). The CTLA-
4 and the Combo group had much more balanced response
between the CD28
2CD95
+ and CD28
+CD95
+ memory popula-
tions with 58% and 65% of their functional response having the
CD28
2CD95
+ phenotype, respectively. Examination of the
proportion of the response that is capable of 4, 3, 2, or 1 function
revealed that the Combo group had the largest proportion of
polyfunctional cells, including 4-function cells, and the lowest
proportion was found in the CTLA-4 group (Figure 4c,d). Taken
together, although CTLA-4 is able to augment the CD4
+ T cell
proliferative response, 4-1BB produces higher frequency poly-
functional CD8
+ T cell responses, consistent with the idea of an
induction of a more effector-like population by this costimulatory
adjuvant.
Memory T cell responses
For an immunization strategy to be practical and effective,
durable rapidly mobilized immune responses are critical as the
time between immunization and pathogen exposure will likely be
highly variable. To determine if these vaccine induced responses
would be maintained in the memory phase of the immune
Figure 2. CTLA-4 blockade enhances the proliferative capacity of CD4
+ and CD8
+ T cells. Fresh PBMCs isolated after the second
immunization were stained with CFSE and stimulated with SIVgag, env, and pol peptides in vitro for 5 days to determine the proliferative capacity of
antigen-specific cells. The proliferative capacity of the CD4
+(a) and CD8
+ (b) T cell compartments are shown as stacked group mean responses 6
SEM. Statistical differences between groups were determined by a one-way ANOVA with a Tukey post-hoc test.
doi:10.1371/journal.pone.0024250.g002
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immunization by IFN-c ELISpot (Figure 5a). Although we did
observe a contraction in the immune response, the antigen-specific
responses were still maintained at a high frequency in all of the
vaccination groups. The Combo group had the highest memory
IFN-c (3,926 SFU/10
6 PBMCs) and the CTLA-4 group had the
smallest response with 1,653 SFU/10
6 PBMCs. We were also
interested in the ex-vivo proliferative capacity of the memory
response. All of the vaccination groups had similar proliferative
capacities with roughly 5% of CD4
+ T cells proliferating following
SIV antigen stimulation (Figure 5b). The proliferative capacity of
the CD8
+ T cell compartment was maintained at a high level,
which ranged from 14.74% in the 4-1BB group to 24.25% in the
DNA group (Figure 5c). These data suggest that DNA
vaccination with or without adjuvants is capable of inducing
long-lived memory responses capable of robust proliferation.
Modulation of the 4-1BB pathway during vaccination
results in enhanced control of viral replication following
SIVmac251 mucosal challenge
Next, we were interested to examine if these vaccine specific
cellular responses, maintained 10 months after immunization,
could impact viral loads detected in peripheral blood following a
mucosal SIVmac251 mucosal challenge. The animals were
challenged with 25 monkey infectious doses (MID) of SIVmac251
by the intrarectal route up to two times to ensure infection. We
then assessed viral loads every week for two months and every
month thereafter up to 5 months post-challenge (Figure 6). All
animals were synchronized by peak viral loads after confirmation
of SIV infection. At peak viremia the Combo group exhibited a
two-log decrease in viral loads compared to the Saline group
(4.15610
5 and 5.13610
7 RNA copies/ml) (Figure 6a). The DNA
and 4-1BB exhibited an approximate 1.5 log decrease in peak viral
loads compared to the Saline group (2.51610
6 and 2.59610
6
RNA copies/ml). The CTLA-4 group exhibited only a small
reduction in peak viral loads with a 0.9 log decrease (6.35610
6
RNA copies/ml). At set point, 10 weeks following peak viremia,
the CTLA-4 group displayed significantly higher viral loads
compared to the 4-1BB or the Combo group (Tukey test, p,0.01).
This disparity in control of viral replication was sustained
throughout the chronic phase of infection. Taken together, the
blockade of CTLA-4 signalling alone results in immune responses
that have no long term positive effect and perhaps a negative effect
on challenge outcome. In contrast the presence of 4-1BB as a
positive vaccine adjuvant in these studies was very evident. By
week 12 (set point) only the 4-1BB adjuvant group or dual CTLA-
4+4-1BB adjuvant groups had any animals with complete
suppression of viral replication (complete viral control in 2/6 vs
4/6 respectively; Figure 6b and Table 2). This suppression was
maintained to the end of the study at week 25 where now 3/6 in
the 4-1BB adjuvant group and 4/6 in the 4-1BB adjuvant+CTLA-
4 group completely controlled viral replication (Figure 6c and
Table 2). Further negative effects of the CTLA-4 group were
apparent at 25 weeks post challenge as this group exhibited the
highest viral titers of any group in the study. 4-1BB appears to be
an important adjuvant for driving improved effector function
which can impact viral challenge outcome in this model.
Discussion
Cell-mediated immunity, particularly CD8
+ T cell-mediated
immunity, has been implicated in controlling HIV replication in
humans and has been shown to be capable of inhibiting viral
replication in SIV-infected macaques [15,16], suggesting that
vaccines targeting cellular immunity may be beneficial for
controlling HIV infection. In this regard, studies have reported
that induction of T cell expansion may be important in control of
HIV infection [17,18,19,20]. Recently, the induction of an effector
phenotype has been suggested to be an important mechanism for
inducing vaccine control of SIV infection [21]. We sought to test
these two highlighted mechanisms of T cell based immune
responses in a novel DNA vaccine model where, through specific
molecular adjuvants that target different costimulatory pathways,
we would drive primarily either significant T cell expansion or T
cell effector function.
The need for improvement in DNA vaccine potency has been a
topic of considerable attention. Multiple optimization techniques,
including codon optimization, RNA optimization, generation of
consensus sequences, and the addition of an efficient leader
sequence, have resulted in the enhanced immunogenicity of
plasmid DNA [22,23,24,25,26]. To further enhance the efficacy of
DNA vaccination, a number of adjuvants have been investigated
[22,23,24,27]. In this regard, targeting of important costimulatory
pathways through modulation of negative and positive signalling is
an attractive strategy for adjuvanting antigen-specific immune
responses during vaccination and is also currently being heavily
investigated for use in cancer immunotherapy. In the current
report we sought to extend such studies into the HIV/SIV vaccine
arena. Here we focused on the ability of a blocking mAb to target
the inhibitory CTLA-4 costimulatory molecule or an agonist mAb
which targets the activating 4-1BB costimulatory molecule to
enhance or modulate the immune response against an engineered
SIV DNA vaccine in the cynomolgus macaque model system.
The results of our study show improved IFN-c ELISpots in
animals that received the 4-1BB mAb adjuvant, suggesting that
stimulating 4-1BB during the induction of a vaccine driven
immune response has the potential to augment Th1-biased cellular
immunity. Furthermore, the CD8
+ T cell functional response
exhibited a memory phenotype that was skewed more toward an
effector phenotype (CD28
2CD95
+) compared to animals that
received the CTLA-4 mAb adjuvant, suggesting a differential
capacity of these two adjuvants to drive effector phenotypes. In
contrast, blockade of CTLA-4 drove more robust T cell expansion
than 4-1BB ligation. Following challenge, the animals receiving
both the 4-1BB and CTLA-4 antibodies exhibited a 2 -log
decrease in peak viral loads compared to the control animals and
significantly lower viral loads compared to the CTLA-4 animals or
the DNA only vaccinated animals. By 12 weeks post challenge 6/
12 animals which received the 4-1BB adjuvant in some form
completely controlled the SIV challenge. This control persisted
Figure 3. Polyfunctional profile of CD4
+ T cells. PBMCs isolated 2 weeks after the fourth immunization were stimulated in vitro with a SIVpol
peptide pool mix for 5 hours. Cells were stained for intracellular production of IFN-c, TNF-a and IL-2 and degranulation by CD107a. The magnitude of
the SIVgag (white), env (grey) and pol (black) responses are shown as stacked means 6 SEM for each group (a). The percentage of the total functional
response that has a CD28
2CD95
+ (black bar) or CD28
+CD95
+ (white bar) is shown as group means 6 SEM (b). Pie charts show the proportion of
antigen-specific CD4
+ T cells that have 4 functions (purple), 3 functions (yellow), 2 functions (green) or 1 function (light blue) (c). The bar graphs
depict the absolute frequency of each of the 15 functional combinations for the DNA (red), 4-1BB (blue), CTLA-4 (orange), Combo (green) and Saline
(black) groups in response to SIVgag, env, and pol after background subtraction (d).
doi:10.1371/journal.pone.0024250.g003
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1BB adjuvant completely controlled the robust SIV challenge.
The outcome of this challenge supports the notion that effector
function is more important for control of viral load in the SIV
model than T cell expansion which is in agreement with a
previously published SIV challenge study [21]. However, it is likely
that both effector function and proliferative capacity are both
important and that the relative ability to expand T cells of the
correct phenotype is ultimately what may have influenced
challenge outcome. This is evidenced by the better control of
viral replication seen in the combined CTLA-4+4-1BB adjuvant
group which had the best control of virus with 4/6 animals
controlling VL to base line levels by the end of the study.
Nasta et al. have demonstrated that, in mice, CTLA-4 signalling
inhibits the Th2-driving transcription factor GATA-3 [11] and
that CTLA-4 blockade increases the levels of GATA-3 in cells,
driving them toward a Th2 phenotype [28]. Consistent with these
previous reports, we observed an increase in the number of cells
secreting the prototypical Th2 cytokine IL-4, as measured by
ELISpot in animals receiving CTLA-4 blockade. However, despite
Figure 5. Maintenance of memory T cells. PBMCs were collected from immunized macaques at 10 months following a fourth immunization to
evaluate memory IFN-c responses. Cells were then stimulated with SIVmac239 gag (white bars), env (grey bars), and pol (black bars) peptide pools in
18-hour IFN-c ELISpot assays (a). PBMCs were also labelled with CFSE and stimulated with pooled SIVmac239 gag (white bars), env (grey bars), and
pol (black bars) peptides for 5 days. Cells were then stained for phenotypic markers and analyzed by flow cytometry to determine the proliferative
response to each antigen (b and c). For both ELISpot and proliferation assays, error bars represent mean responses 6 SEM.
doi:10.1371/journal.pone.0024250.g005
Figure 4. Polyfunctional profile of CD8
+ T cells. PBMCs isolated 2 weeks after the fourth immunization were stimulated in vitro with a SIVpol
peptide pool mix for 5 hours. Cells were stained for intracellular production of IFN-c, TNF-a and IL-2 and degranulation by CD107a. The magnitude of
the SIVgag (white), env (grey) and pol (black) responses are shown as stacked means 6 SEM for each group (a). The percentage of the total functional
response that has a CD28
2CD95
+ (black bar) or CD28
+CD95
+ (white bar) is shown as group means 6 SEM (b). Pie charts show the proportion of
antigen-specific CD8
+ T cells that have 4 functions (purple), 3 functions (yellow), 2 functions (green) or 1 function (light blue) (c). The bar graphs
depict the absolute frequency of each of the 15 functional combinations for the DNA (red), 4-1BB (blue), CTLA-4 (orange), Combo (green) and Saline
(black) groups in response to SIVgag, env, and pol after background subtraction (d).
doi:10.1371/journal.pone.0024250.g004
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responses mediated primarily by CD8
+ T cells, suggesting that,
while there were more IL-4-secreting cells, the response was still
predominantly Th1-mediated. Interestingly, antigen-specific pro-
liferation of peptide-stimulated CD4
+ T cells ex vivo was
significantly higher in the group receiving the CTLA-4 blockade
in vivo over animals receiving DNA immunizations in the absence
of CTLA-4 blockade, demonstrating the ability of blocking
CTLA-4 antibodies to enhance CD4
+ T cell activity. It should
be noted that while CTLA-4 blockade enhanced proliferative
capacity, other cellular functions such as degranulation and TNF-
a secretion by CD8
+ T cells were highest in immunized animals
not receiving blocking CTLA-4 antibodies.
The group receiving both adjuvants had intermediate levels of
responses by IFN-c ELISpot and CD4
+ T cell proliferation, but
the highest magnitude of cytokine producing cells and the largest
proportion of polyfunctional CD8
+ T cells. Following challenge,
only this group had a significant, 2-log, reduction viral replication
compared to the Saline controls. At viral set point, 4 out of the 6
animals receiving both adjuvants had undetectable viral loads, and
this control was maintained out to 20 weeks post-challenge.
Given the results of the SIVmac251 challenge, it appears that
the induction of strong CD8
+ effector T cell response may have a
larger impact on viral replication than a highly proliferative CD4
+
T cell response. This is not surprising as previous studies have
highlighted the importance of generating effector T cells during
vaccination [21] and due to the fact that a highly proliferative
CD4
+ T cell response may only exacerbate the disease state by
providing the virus with activated target cells, as opposed to
generating potent anti-viral immunity. This is the first study to
demonstrate the ability of a novel DNA-based vaccine adjuvanted
by mAbs to the costimulatory molecules 41BB and CTLA4 to
induce robust cellular effector immune responses which subse-
quently lead to significant control of a high dose mucosal
SIVmac251 challenge. The study suggests that adjuvants that
expand particular T cell effector phenotypes are likely important
in SIV viral control. These studies have implications for the
development of HIV vaccine strategies.
Materials and Methods
Animals
Thirty cynomolgus macaques (Macaca fascicularis) were pur-
chased from Charles River BRF (Houston, TX) and housed at the
Bristol-Myers Squibb (BMS) Lawrenceville Facility (Princeton, NJ)
and consisted of 11 females and 19 males between 3 and 8 years of
age and weighing from 2.7 to 7.7 kg.
Ethics Statement
The Bristol-Myers Squibb Animal Care and Use Committee
addresses Animal Facilities, Contract Facilities, and Animal
Suppliers. In addition, the animal facility is accredited by the
Association for Assessment and Accreditation of Laboratory
Animal Care. Following vaccination, animals were moved to
BIOQUAL, Inc. in Rockville, MD for challenge. BIOQUAL is
AAALAC, OLAW, and USDA accredited. The protocol was
approved by Bristol-Myers Squibb Animal Care and Use
Committee addresses Animal Facilities and BIOQUAL’s Institu-
tional Animal care and Use Committee under OLAW Assurance
Number of A-3086-01. At all locations, animals were handled
based on the recommendations in the Guide for the Care and Use
of Laboratory Animals of the National Institutes of Health and
animal welfare was ensured and steps taken to ameliorate suffering
Figure 6. Modulation of the 4-1BB pathway during vaccination results in enhanced control of viral replication following SIVmac251
mucosal challenge. To test the efficacy of the vaccine-induced immune response the animals were challenged with a high-dose, intrarectal
SIVmac251 challenge ten months following the fifth immunization. We then assessed viral loads every week for two months and every month
thereafter up to 5 months post-challenge. The viral load data were graphed with the group means shown. (a). Viral loads were compared at peak
viremia (2 weeks post challenge), (b.) set point (12 weeks post-challenge) and (c.) during chronic infection (20–24 weeks post-challenge). Statistical
analysis was performed by log transforming the viral loads to normalize the data and used in a one-way ANOVA with a Tukey post-hoc test with p
values of ,0.05 (*) or ,0.01 (**) indicated.
doi:10.1371/journal.pone.0024250.g006
Table 2. Animals with Complete Viral Suppression.
Group Setpoint Chronic
Ratio Percentage Ratio Percentage
DNA 0/6 0.0 1/6 16.7
4-1BB 2/6 33.3 3/6 50.0
CTLA-4 0/6 0.0 0/6 0.0
4-1BB+CTLA-4 4/6 66.7 4/6 66.7
Saline 0/5 0.0 1/5 20.0
doi:10.1371/journal.pone.0024250.t002
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‘‘The use of non-human primates in research.’’
DNA vaccine
The plasmids used in this study express the modified proteins
for SIV Gag (pSIVgag), SIV pol (pSIVpol) or SIV env (pSIVenv),
and were generated in David Weiner’s laboratory. Briefly,
consensus sequences for macaque SIV gag, SIV env, and SIV
pol were generated with several modifications. SIV gag was
modified with the addition of a constitutive transport element. In
addition, SIV env V1 and V2 regions were shortened by removing
N-linked glycosylation sites and the cytoplasmic tail was truncated
to prevent envelope recycling. For SIV pol, 7 mutations were
introduced to deactivate the protease, reverse transcriptase,
RNAse H, and integrase regions. An efficient IgE leader sequence
was added to all SIV antigen sequences to improve expression.
The resulting optimized SIV DNA immunogens were codon- and
RNA-optimized, synthesized, and cloned into the pVAX1
expression vector by GENEART (Toronto, ON) to create
optimized expression constructs for SIV gag (pSIVgag), SIV env
(pSIVenv), and SIV pol (pSIVpol). These constructs were then
sent to Aldevron (Fargo, ND) for large-scale production. Purified
plasmid DNA was formulated in 0.15 M citrate buffer pH 6.7
with 0.25% bupivicaine in water.
Antibodies
Ipilimumab (MDX-010, lot #6G19359), a fully human IgG1
antibody to human CTLA-4, was supplied as drug product in
vials, ready to use for injection, by Pharmaceutics Research
Institute, Bristol-Myers Squibb, Candiac, Quebec, Canada. BMS-
663513 (lot #6A20383), a fully human IgG4 antibody to human 4-
1BB, was formulated in 5 mM sodium succinate buffer, pH 5,
containing 2 mg/mL poloxamer 188 in 0.9% sodium chloride for
injection, USP. Antibodies were administered intravenously by
manual infusion at an approximate rate of 3 mL/minute. Several
antibodies were used for flow cytometry staining; APC-Cy7-
conjugated anti-CD3 (clone SP34-2), PerCP-Cy5.5-conjugated
anti-CD4 (clone L200), Pacific Blue-conjugated anti-CD14 (clone
M5E2), Pacific Blue-conjugated anti-CD16 (clone 3G8), PE-Cy5-
conjugated anti-CD95 (clone DX2), FITC-conjugated CD107a
(clone H4A3), PE-Cy7-conjugated anti-TNF-a (clone Mab11),
Alexa Fluor 700-conjugated anti-IFN-c (clone B27) (all from BD
Pharmingen, San Diego, CA), Pacific Blue-conjugated anti-CD19
(clone SJ25-C1) (Invitrogen, Carlsbad, CA), Pacific Orange-
conjugated anti-CD8 (clone RPA-T8) (kindly provided by Dr.
Michael Betts at the University of Pennsylvania), and ECD-
conjugated anti-CD28 (clone CD28.2) (Beckman Coulter).
Study design and sample collection
Experimental groups contained 2 females and 4 males weighing
between 2.7 and 4.8 kg. The control group contained 3 females
and 3 males weighing between 4.0 and 7.7 kg. Animals were
immunized with 2 mg each of pSIVgag, pSIVpol and pSIVenv
i.m. divided into 2 doses administered on consecutive days on
study weeks 0, 4, 8, 12, and 90. Each immunization was given in
2 mL on each day (total of 3 mg/day) into 4 sites (0.5 mL/site).
Control animals were injected with 0.25% bupivicaine in 0.9%
sodium chloride (vaccine vehicle) under the same conditions.
On Study Days 4, 9, 30, 32, 58, 60, 86, and 88 (weeks 0, 4, 8,
and 12), animals in the antibody treatment groups received
10 mg/kg of Ipilimumab (2 mL/kg) i.v. and/or 10 mg/kg of anti-
4-1BB antibody (5 mL/kg) at an approximate rate of 3 mL/
minute. On the days of antibody infusion, animals in the control
group or the DNA-only immunized group were injected i.v. with
0.9% sodium chloride.
PBMC Isolation
Blood was collected in EDTA tubes and diluted 1:2 in HBSS.
Percoll (GE Healthcare, Piscataway, NJ) stock solution was made
by combining 360 mL Percoll with 40 mL 1.5 M NaCl solution.
Percoll working solution was made by combining 140 mL Percoll
stock solution with 102 mL 0.15 M NaCl solution. Diluted blood
was layered on top of 10 mL Percoll working solution and
centrifuged at 1200 RPM for 40 minutes. The PBMC layer
(interface) was collected and washed with HBSS. Residual red
blood cells were lysed using ACK lysing buffer (Lonza, Walkers-
ville, MD). PBMCs were then washed and incubated in RPMI
1640 containing 2 mM L-glutamine, 100 IU/mL penicillin and
100 IU/mL streptomycin, 55 mM 2-mercaptoethanol, and 10%
fetal bovine serum (R10 medium) overnight at 37uC.
Synthetic peptides. Peptides used in this study were
obtained from the National Institutes of Health AIDS Reagent
and Reference Reagent Program (NIH Repository, Bethesda,
MD). One hundred and twenty five, two hundred and eighteen,
and two hundred and sixty three peptides corresponding to the
complete sequence of SIVmac239 Gag, Env and Pol, respectively,
were used. Peptides were 15 amino acids in length with 11-amino
acid overlap. These peptides were resuspended in DMSO and
divided into pools. Gag was divided into 3 pools (peptides 1–41 for
pool 1, 42–83 for pool 2, and 84–125 for pool 3), Env was divided
into 4 pools (peptides 1–54 for pool 1, 55–108 for pool 2, 109–163
for pool 3, and 164–218 for pool 4), and Pol was divided into 5
pools (peptides 1–53 for pool 1, 54–106 for pool 2, 107–158 for
pool 3, 159–210 for pool 4, and 211–263 for pool 5), which were
labeled utilizing consecutive numbers designed by the NIH
Repository. Each pool of peptides was stored at 220uC until use.
ELISPOT assays. IFN-c production was measured by
ELISpot assay. MultiScreen
TM-IP 96-well plates (Millipore,
Bedford, MA) were coated overnight at 4uC with capture
antibody diluted in PBS at a concentration of 7.5 mg/mL (anti-
IFN-c clone GZ-4, Mabtech, Cincinnati, OH). Plates were washed
five times with PBS and blocked with R10 overnight at 4uC. Plates
were washed twice with PBS and macaque lymphocytes were
added in duplicate at an input cell number of 2610
5/well in
100 ml R10. For third and fourth immunization and memory
timepoints, the input cell number was decreased to 1610
5 cells
due to excessive spot number. SIV peptide pools were diluted 1/
200 in R10 and 100 ml were added per well (final 1/400 dilution).
Cells incubated in R10 with DMSO (carrier) or stimulated with
ConA (5 mg/ml; Sigma Chemical Co., St. Louis, MO) were used
as negative and positive controls, respectively. Plates were
incubated overnight at 37uC, washed five times with PBS and
incubated overnight at 4uC with 100 ml/well of biotinylated
detection antibody diluted in PBS (1 mg/mL; clone 7-B6-1,
Mabtech). Plates were washed five times with PBS and then
incubated with 100 ml/well of streptavidin-alkaline phosphatase
diluted in PBS (1:1000) for 1 hour at room temperature. Plates
were then washed five times with PBS and developed with 100 ml/
well BCIP/NBT substrate solution for 5–10 minutes at room
temperature. Plates were washed with water, air-dried and the
spots counted using an automated ELISpot reader system (CTL
Analyzers, OH) with the ImmunoSpotH software. The mean
number of spots from duplicate or triplicate wells was adjusted to
1610
6 PBMC. The SIV-specific responses were calculated after
subtraction of spots formed in response to R10 alone and the net
values were then added. The majority of background values
ranged from 0 to 25 IFN-c spots/well. For some experiments,
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+ T cells were depleted using anti-CD8 Dynabeads
(Invitrogen) just prior to plating cells to determine the CD8
+ T-
cell contribution to the ELISpot number.
IL-4 ELISpot assays were performed similar to IFN-c ELISpot
assays. Frozen cells were thawed and rested overnight in R10.
Cells were then counted and IL-4 ELISpot assays were performed
using anti-IL-4 coating antibody (clone 82.4) and biotinylated anti-
IL-4 detection antibody (clone 12.1) (both from Mabtech).
CFSE labeling and flow cytometry
Freshly isolated PBMCs were stained with 5 mM CFSE
(Invitrogen) in pre-warmed PBS for 10 minutes, washed 3 times,
and suspended in R10. Cells were stimulated using either pooled
peptides from SIVgag, SIVenv, and SIVpol (NIH Repository) or
5 mg/mL Concanavalin A (ConA) (Sigma) for 5 days. Six hours
prior to the end of the incubation period, GolgiStop and GolgiPlug
(both from BD Pharmingen) were added to the cells to inhibit
protein transport. Cells were then washed in PBS and stained
using the LIVE/DEAD Fixable Violet Dead Cell Stain Kit
(Invitrogen) and subsequently stained for CD3, CD4, CD8, CD14,
CD16, and CD19. Antibodies were incubated with cells for
30 min on ice. After washing with FACS buffer (PBS with 1%
heat-inactivated FCS and 0.1% sodium azide, cells were fixed with
1% paraformaldehyde. For flow cytometry, cells were gated on
singlets using FSC-H by FSC-A followed by gating on Pacific
Blue-low, CD3
+ T cells to examine T-cell populations.
For intracellular cytokine staining, fresh PBMCs are stimulated
with pooled SIVPol peptides for 6 hours in the presence of
GolgiStop and GolgiPlug and with the addition of CD107a as an
enhanced stain. Following the 6-hour incubation, cells were
washed in PBS twice and stained using LIVE/DEAD Fixable
Violet Dead Cell Stain Kit for 10 minutes at 37uC. Following the
incubation, antibodies to detect CD4, CD8, CD14, CD16, CD19,
CD28, and CD95 were added and samples incubated for
30 minutes at 4uC. Cells were washed three times in FACS buffer
and stained for CD3, and cytokines using the BD Cytofix/
cytoperm kit. Cells were then washed twice and fixed with 1%
paraformaldehyde for flow cytometry, gating on Pacific Blue-low,
CD3
+ T cells. Functionality was assessed using FlowJo analysis
followed by Pestle and Spice software (kindly provided by Dr.
Mario Roederer).
Challenge
Animals were challenged intrarectally with SIVmac251 on
study week 119. Viral stock was provided by Hanne Andersen at
BIOQUAL, Inc and diluted 1:50 for challenge. Viral loads were
monitored following the challenge. Animals that had no detectable
viral load were re-challenged on study week 124.
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